The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.40
Bid: 9.00
Ask: 9.80
Change: 0.25 (2.73%)
Spread: 0.80 (8.889%)
Open: 9.15
High: 9.40
Low: 9.15
Prev. Close: 9.15
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DIRECTOR DEALINGS: MD of Gleeson Homes buys GBP150,000 in shares

Tue, 02nd Nov 2021 15:20

(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Tuesday and not separately reported by Alliance News:

----------

MJ Gleeson PLC - Sheffield, England-based housebuilder - Mark Knight, managing director of Gleeson Homes, buys 18,795 shares at GBP7.94, worth GBP149,232, on Monday. Knight now has 33,682 shares, a 0.1% stake.

----------

accesso Technology Group PLC - Berkshire, England-based provider of software for leisure, entertainment and cultural sectors - Non-Executive Chair Bill Russell buys 8,200 shares at USD12.37, worth USD101,393, in the US on Friday last week. Now has 53,507 shares, a 0.1% stake.

----------

Riverstone Credit Opportunities Income PLC - aims to generate returns by making loans to companies in energy sector - Director Reuben Jeffery buys 50,000 shares at USD0.86, worth USD43,130, on Monday.

----------

International Biotechnology Trust PLC - investment trust run by SV Health Managers LLP - Non-Executive Director Patrick Magee buys 4,000 shares at 735 pence, worth GBP29,400, on Tuesday. Now has 7,500 shares.

----------

Headlam Group PLC - Birmingham-based floorcoverings distributor - Independent Non-Executive Director Stephen Bird buys 5,000 shares at 462.60p, worth GBP23,130, on Monday.

----------

Scancell Holdings PLC - Oxford, England-based immunotherapies for treatment of cancer and infectious disease - Non-Executive Director Martin Diggle buys 100,000 shares via Vulpes Life Sciences Fund at 19 pence, worth about GBP19,000, on Friday last week. Vulpes now has 117.3 million shares, a 14.4% stake.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
22 Jul 2020 11:24

IN BRIEF: Scancell To Raise GBP15 Million Via Share, Loan Note Issue

IN BRIEF: Scancell To Raise GBP15 Million Via Share, Loan Note Issue

Read more
24 Jun 2020 12:18

Scancell To Start Clinical Trial For Cancer Treatment In 2021

Scancell To Start Clinical Trial For Cancer Treatment In 2021

Read more
12 Jun 2020 12:59

Scancell upbeat on publication of AvidiMab research

(Sharecast News) - Cancer immunotherapy developer Scancell Holdings noted the publication of its manuscript in Cancer Research, a journal of the American Association of Cancer Research (AACR) on Friday, titled 'Engineering the human Fc-region enables direct cell killing by cancer glycan-targeting antibodies without the need for immune effector cells or complement'.

Read more
28 Apr 2020 16:40

Director dealings: Scancell director lowers stake

(Sharecast News) - Scancell revealed on Tuesday that non-executive director Martin Diggle had sold 1.5m ordinary shares in the AIM-listed biotechnology firm.

Read more
28 Apr 2020 14:43

UK DIRECTOR DEALINGS SUMMARY: Citrus Buys More easyHotel At Exit Price

UK DIRECTOR DEALINGS SUMMARY: Citrus Buys More easyHotel At Exit Price

Read more
24 Apr 2020 12:00

Scancell Rises On Launch Of Covid-19 Vaccine Research Programme

Scancell Rises On Launch Of Covid-19 Vaccine Research Programme

Read more
24 Apr 2020 10:49

UK WINNERS & LOSERS SUMMARY: FirstGroup Rises On Liquidity Boost

UK WINNERS & LOSERS SUMMARY: FirstGroup Rises On Liquidity Boost

Read more
3 Feb 2020 14:20

Scancell's 'SCIB1' clears latest regulatory hurdle in US

(Sharecast News) - Cancer immunotherapy developer Scancell announced on Monday that its investigational new drug (IND) application to the United States Food and Drug Administration (FDA) for 'SCIB1' has been approved.

Read more
3 Feb 2020 10:44

Scancell Gets US FDA Approval For SCIB1 Drug Application

Scancell Gets US FDA Approval For SCIB1 Drug Application

Read more
31 Jan 2020 11:12

Scancell Interim Loss Narrows, Progresses On Product Pipeline

Scancell Interim Loss Narrows, Progresses On Product Pipeline

Read more
20 Jan 2020 12:04

Scancell Teams To Evaluate Its Antibody Platform For Cancer Treatment

Scancell Teams To Evaluate Its Antibody Platform For Cancer Treatment

Read more
18 Dec 2019 16:29

DIRECTOR DEALINGS: Scancell Non-Executive Diggle Buys 3 Million Shares

DIRECTOR DEALINGS: Scancell Non-Executive Diggle Buys 3 Million Shares

Read more
16 Dec 2019 13:30

Scancell inks AvidiMab agreement with Chinese biotech company

(Sharecast News) - Scancell Holdings on Monday signed a collaboration and non-exclusive research agreement with an unnamed Chinese biotechnology firm.

Read more
16 Dec 2019 09:21

Scancell Shares Jump As It Secures First Deal In China For AvidiMab

Scancell Shares Jump As It Secures First Deal In China For AvidiMab

Read more
12 Dec 2019 14:23

Oxford Technology VCTs Report Mixed Third-Quarter Performances

Oxford Technology VCTs Report Mixed Third-Quarter Performances

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.